DIRS.INFO The most relevant business & tech news

Kam Ghaffarian, co-founder and chairman of Axiom Space Inc., speaks during an interview at the company's headquarters in Houston, Texas, U.S., on Friday, Jan. 14, 2022. IBX's Kam Ghaffarian wants to go even further: the stars. Ghaffarian has been instrumental in ushering in the new space economy, having co-founded and invested in a cadre of commercial space ventures. Unlike other high-profile billionaires building commercial space companies, Ghaffarian made his fortune through the space industry, and rather than focusing on access to space, he's leveraging those falling costs to build out infrastructure and business activities in space. Ghaffarian believes the space economy will be worth trillions of dollars — and sooner than many realize.

Persons: Kam Ghaffarian, Jeff Bezos, Richard Branson, Elon Musk, IBX's Kam Ghaffarian, CNBC's Morgan Brennan, Ghaffarian, Odysseus, he's, We've, Jeff, Bezos, we've, Morgan Brennan, it's Organizations: Space, International, Elon, Technologies, NASA, KBR, SpaceX Locations: Houston , Texas, U.S, Colorado Springs, Iran

☆ Supreme Court medication abortion case threatens ‘seismic shift’ in FDA drug approval process, experts warn
▼ + stars: | 2024-03-26 | by ( Meg Tirrell | Tierney Sneed | ) edition.cnn.com time to read: +7 min

If the Supreme Court agrees with the appeals court, the approval of mifepristone could be reset to where it stood before 2016, limiting telehealth access to medication abortion and reimplementing other restrictions. “Nevertheless, drug developers invest in new medicines because, if their investments succeed, FDA’s rigorous drug approvals and subsequent regulatory actions are sturdy enough to facilitate reliable returns. “And without necessary investment, drug development would freeze, stifling innovation and limiting treatment options for patients.”Of course, if the Supreme Court upholds the appeals court decision, the most immediate impact would be to mifepristone itself. “It is both my hope and my ‘bet’ that the court doesn’t uphold the 5th Circuit on the standing argument,” Cohen wrote. “But I have learned the Supreme Court is hard to predict much of the time.”

Persons: thalidomide, mifepristone that’s, ”, Daniel Grossman, ” Grossman, ” PhRMA, Glenn Cohen, Dr, Sanjay Gupta, Cohen, ” Cohen Organizations: CNN, Food and Drug, Federal Food, FDA, US, University of California San, Reproductive, Guttmacher Institute, Circuit, Appeals, Pharmaceutical Research, Manufacturers of America, Harvard Law School, CNN Health Locations: Massengill, University of California San Francisco, Texas

☆ JPMorgan CEO Jamie Dimon says AI is not just hype — 'This is real'
▼ + stars: | 2024-02-26 | by ( Jesse Pound | In Jesse-Pound | ) www.cnbc.com time to read: +1 min

The burgeoning artificial intelligence tools from companies such as OpenAI still have their share of skeptics, but don't count JPMorgan Chase CEO Jamie Dimon among them. It's real," Dimon said. JPMorgan has done work on the ability to use the new technologies internally, with Dimon saying that AI will eventually "be used in almost every job." JPMorgan created a new role of chief data and analytics officer last year, in part to handle AI. Dimon said Monday that there are 200 people at JPMorgan doing research on the large language models that have recently been rolled out by tech companies.

Persons: Jamie Dimon, CNBC's Leslie Picker, Dimon Organizations: JPMorgan Chase, JPMorgan, CNBC PRO

☆ Federal judge tosses lobbying group's lawsuit challenging Medicare drug price negotiations
▼ + stars: | 2024-02-13 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

The decision is an early win for the Biden administration as it grapples with a flurry of other legal challenges that drugmakers have filed against the Medicare drug price negotiations. The judge's ruling won't end the legal battle over the policy, which could end up at the Supreme Court. A slate of major companies with drugs selected for negotiations, including J&J, Merck , and Bristol Myers Squibb , have filed separate lawsuits challenging the constitutionality of the price talks. The suit also argued that the price talks violate the Eighth Amendment because they include a "crippling" excise tax aimed at forcing drugmakers to accept the government-dictated price of medicines. The groups also argued that the price talks violate due process by denying pharmaceutical companies and the public input on how Medicare negotiations will be implemented.

Persons: Biden, drugmakers, Judge David Ezra of, Ezra, NICA's, Nicole Longo, PhRMA, Eli Lilly, Johnson, NICA Organizations: U.S . Department of Health, Human Services, Supreme, Medicare, Western, Western District of Texas, Pharmaceutical Research, Manufacturers of America, Global Colon Cancer Association, National, Center Association, CNBC, Pfizer, Johnson, Merck, Bristol Myers Squibb, Chamber of Commerce, Department of Health, Department of Justice Locations: Washington ,, Western District, PhRMA, Ohio

And so I’m going to ask you, to follow me in taking our America First movement to the next level,” Ramaswamy said. In a rapid-fire presentation on a range of issues, Ramaswamy wowed many GOP audiences by seamlessly mixing his biography and detailed policy positions with conservative talking points. He questioned the government’s account of the Sept. 11, 2001, attacks and called for firing 75% of the federal workforce. Yet alongside the bravado, Ramaswamy often ignored contradictory details, and his confidence sometimes brought him trouble. Ramaswamy insisted he had a nobler purpose: “I’ll keep us out of World War III and then revive national pride in this country.”

Persons: Ramaswamy, Ron DeSantis, Nikki Haley, ” Ramaswamy, Ramaswamy needled, Trump, ”, Ramaswamy wowed, “ Dick Cheney, “, Sean Hannity Organizations: Florida Gov, Trump, Republican, Harvard University, Yale Law School, America, GOP, U.S, Capitol, Fox News Locations: Iowa, Florida, Israel, Ukraine, ”, American

download the appSign up to get the inside scoop on today’s biggest stories in markets, tech, and business — delivered daily. In a 15-second video released to YouTube on Wednesday night, President Joe Biden promised the move would lower prices. It's the latest health policy pitch from a White House gearing up to make its efforts to tackle drug prices a central theme in next year's reelection campaign. Pharmaceutical companies have pushed back on the idea that prices alone are enough for Washington to act against a drug's patent. The plan could threaten future drugs, according to the pharmaceutical lobbying firm Pharmaceutical Research and Manufacturers of America, or PhRMA.

Persons: —, Biden, Joe Biden, Elizabeth Warren of Massachusetts, Amy Klobuchar, Neera Tanden, Megan Van Etten, William Pierce, George W, Pierce Organizations: Service, Business, YouTube, White, Medicare, Health, Human Services, Pharmaceutical, Pharmaceutical Research, Manufacturers of America, HHS Locations: WASHINGTON, Sens, Minnesota, Washington

☆ Eli Lilly vs. Novo Nordisk: The pros deliver their verdict on the viral weight-loss stocks
▼ + stars: | 2023-12-06 | by ( Amala Balakrishner | ) www.cnbc.com time to read: +4 min

It has been quite a year for both Eli Lilly and Novo Nordisk given the boom in weight-loss drugs. Shares in Eli Lilly are up around 60% year-to-date, while its Danish counterpart Novo Nordisk has seen a gain of around 50%. At present, both Eli Lilly and Novo Nordisk offer weight loss treatments. Novo Nordisk Novo Nordisk's Wegovy recently made headlines for reducing the risk of heart attacks and strokes by 20% in adults with heart disease and obesity. Aside from Eli Lilly and Novo Nordisk, Pfizer , Johnson & Johnson and AstraZeneca are also developing weight-loss drugs.

Persons: Eli Lilly, Stocks, Rahul Ghosh, Rowe Price, TRP's Ghosh, Eli Lilly's, Ghosh, FactSet, Lilly, Novo Nordisk Novo Nordisk's Wegovy, Elizabeth Field, Squawk, What's, it's, Michael Bloom Organizations: Novo Nordisk, Nordisk, CNBC Pro, U.S . Food, Administration, pharma, Novo Nordisk Novo Nordisk's, Heart Association Scientific, Citi, Pfizer, Johnson, AstraZeneca, Barclays Locations: Danish, U.S, Novo

The full benefit for these Indian manufacturers will not be immediate, said Peter DeYoung, CEO of Piramal Pharma Solutions. Nimgaonkar said Indian CDMOs need to do more to ensure their reputation on quality standards matches Western and Chinese ones. The Indian CDMOs told Reuters that their facilities are routinely inspected by the FDA. Aragen counts seven of the 10 biggest pharma companies as clients, he said, declining to name them. "New biotechs are deciding to put eggs in both the Indian and China baskets from the start," Subramanian said.

Persons: Trump, Tommy Erdei, Ashish Nimgaonkar, Nimgaonkar, Sai, Peter DeYoung, Helen Chen, CDMOs, Piramal, DeYoung, Ramesh Subramanian, Subramanian, Maggie Fick, Andrew Silver, Michele Gershberg, Catherine Evans Organizations: Jefferies, Glyscend Therapeutics, Reuters, Sciences, Piramal Pharma, Sai Life Sciences, Western pharma, Piramal Pharma Solutions, L.E.K, Consulting, pharma, U.S . Food, Drug Administration, FDA, Thomson Locations: China, India, SHANGHAI, HYDERABAD, U.S, Shanghai, United States, London, Hyderabad

☆ Wegovy slashes risk of serious heart events: What this means for patients and insurers
▼ + stars: | 2023-11-13 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWegovy slashes risk of serious heart events: What this means for patients and insurersEmily Field, head of European Pharmaceutical Research at Barclays, joins 'Squawk Box' to discuss a new study that suggests that the weight-loss drug Wegovy reduces the risks of heart attacks, what these results mean for patients and insurers, and more.

Persons: Emily Field Organizations: European Pharmaceutical Research, Barclays

U.S. President Joe Biden delivers remarks on Social Security and Medicare at the University of Tampa in Tampa, Florida, U.S. February 9, 2023. The ruling is the first to come from multiple lawsuits by drug companies and industry groups challenging the program. The drug price negotiation program is part of the Inflation Reduction Act, which Biden, a Democrat, signed last year. The Biden administration has repeatedly said there is nothing in the Constitution that prohibits drug price negotiations. Many other countries already negotiate drug prices.

Persons: Joe Biden, Jonathan Ernst, vindicating, Joe Biden's, Michael Newman, Biden, drugmakers, Newman, Karine Jean, Pierre, Donald Trump, Johnson, Januvia, Bristol Myers, Boehringer, Brendan Pierson, Nate Raymond, Costas Pitas, Alexia Garamfalvi, Bill Berkrot, Chris Reese, Leslie Adler Organizations: Social Security, University of Tampa, REUTERS, U.S, District, U.S . Chamber of Commerce, Medicare, Commerce, U.S . Justice, Republicans, Big Pharma, Republican, U.S . Centers, Medicaid Service, CMS, Bristol Myers Squibb, Pfizer, Johnson, Merck, Co's, Pharmaceutical Research, Manufacturers of America, Companies, Thomson Locations: Tampa , Florida, U.S, Dayton , Ohio, New York, Boston

☆ Medicare's drug-price negotiations will save the government billions in healthcare spending — but patients may not feel the benefits
▼ + stars: | 2023-09-25 | by ( Natalie Rahhal | ) www.businessinsider.com time to read: +6 min

Patients with private health insurance aren't likely to see a drop in costs from the negotiations. Longo said the price-setting provisions will drive research and investment away from treatment options for Medicare patients. If drug companies won't come to the negotiating table to lower drug prices paid by private insurers, those insurers could take the companies' drugs off their lists of covered medications. Or, if private insurance companies don't negotiate drug prices down for their patients, patients in some cases could seek out different insurance. "These are not full solutions, but they are the beginning of cracks in the facade" of drug companies' constant price hikes, Feldman said.

Persons: Biden, Juliette Cubanski, Jeffrey Davis, Davis, Richard Frank, —, Nicole Longo, Longo, it's, — aren't, Robin Feldman, Feldman, Cuban's Organizations: Medicare, Healthcare, Morning, Centers, Services, Congressional, McDermott, Consulting, Brookings Schaeffer Initiative, Health, Pharmaceutical Research, Manufacturers of America, PhRMA, University of California Law School, Costco, Pharmaceutical Locations: Lower

A few compounds picked by AI are now in development, but those bets will take years to play out. Reuters interviews with more than a dozen pharmaceutical company executives, drug regulators, public health experts and AI firms show, however, that the technology is playing a sizeable and growing role in human drug trials. The U.S. Food and Drug Administration (FDA) said it had received about 300 applications that incorporate AI or machine learning in drug development from 2016 through 2022. Without AI, Bayer said it would have spent millions more, and taken up to nine months longer to recruit volunteers. Finding real-world patients by mining electronic patient data can be done manually, but using AI speeds up the process dramatically.

Persons: Dado Ruvic, Jeffrey Morgan, Amgen, Badhri Srinivasan, Sameer Pujari, drugmaker Bayer, Bayer, Blythe Adamson, Roche, Richard Pazdur, Gen Li, John Concato, Natalie Grover, Martin Coulter, Julie Steenhuysen, Josephine Mason, David Clarke Organizations: Pharmaceutical Research, REUTERS, Pharmaceutical, Bayer, Novartis, Deloitte, U.S . Food, Drug Administration, Reuters, World Health, Flatiron Health, FDA, European Medicines Agency, FDA's Oncology, Excellence, Medical, FDA's Center, Drug, Research, Thomson Locations: U.S, Johannesburg, Texas, Finland, United States, London, Chicago

☆ Amoxicillin shortage: A new season of infections is here, but the shortage of a common kids’ antibiotic never ended
▼ + stars: | 2023-09-22 | by ( Brenda Goodman | ) edition.cnn.com time to read: +7 min

Respiratory illness season is coming up, and that’s going to be a huge issue,” said David Margraf, a pharmaceutical research scientist with the University of Minnesota’s Resilient Drug Supply Project. During a drug shortage, allocation helps ensure that no single buyer can claim all the available supply. Khazanchi and his colleague Dr. Ryan Brewster recently studied the clinical effects of last winter’s amoxicillin shortage. “Drug shortages will likely continue to increase if the pricing dynamics in the marketplace are not addressed,” Sandoz said in a statement. “The companies refuse to tell us what’s going on,” said Erin Fox, who tracks drug shortages at the University of Utah.

Persons: —, earaches, ”, David Margraf, Selena Ko, Erin Hooley, pediatricians, Rohan Khazanchi, Khazanchi, Ryan Brewster, Amoxicillin, ” Khazanchi, “ It’s, ” Sandoz, Erin Fox, Laura Bray, They’re, ” Margraf, ” Bray, Dr, Sanjay Gupta, “, Matt Christian Organizations: CNN, Food, University of, Project, Rush University Medical Center, Chicago Tribune, TNS, Getty, FDA, Brigham & Women’s Hospital, Teva Pharmaceuticals, Novartis, University of Utah, Angels, CNN Health, US Department of Agriculture, Pharmacopeia’s Medicines Locations: Chicago, Boston

Three-quarters of Americans, or 76%, favor allowing the federal health care program for the elderly to negotiate prices for certain prescription drugs. Americans are split on how Biden is handling the issue of prescription drug prices — 48% approve, making it a relative strong point for Biden, but 50% disapprove. Even among the Americans who support allowing Medicare to negotiate drug prices, approval of Biden’s handling of the issue remains relatively tepid. "They kept prescription drug prices high to increase their profits. “Well, we did it.”Ellen Daily, a 73-year-old retiree in Carrollton, Texas, said she strongly favors allowing Medicare to negotiate on drug prices.

Persons: Joe Biden, trumpeting, drugmakers, Biden, it's, Esperanza Baeza, I'm, ”, “, ” Biden, Ellen Daily, Annie Lok, Lok, doesn’t Organizations: WASHINGTON, Associated Press, NORC, for Public Affairs Research, —, Big Pharma, ”, Medicare, Pharmaceutical Research, Manufacturers of America, Services, Republican Locations: Chicago, Baeza, Carrollton , Texas, Queens , New York

☆ Pot stocks jump as federal agency reportedly seeks to downgrade cannabis from the hard-drug category
▼ + stars: | 2023-08-30 | by ( Filip De Mott | ) www.businessinsider.com time to read: +2 min

The Drug Enforcement Agency received an official recommendation to downgrade marijuana. Currently, pot is classified as a Schedule I drug, on par with heroin. Marijuana's category downgrade would be a serious shift for the cannabis industry, easing restrictions on its use. The largest marijuana exchange traded fund, the AdvisorShares Pure US Cannabis ETF, gained around 19%. It was outpaced by the Roundhill Cannabis ETF, at 20%.

Persons: Anne Milgram, Cronos, SNDL Organizations: Drug Enforcement Agency, Service, Bloomberg, Department of Health, Human Services, Drug, DEA, Cannabis ETF, Cannabis, Aurora Cannabis Locations: Wall, Silicon

☆ The ADHD drug market is already stretched thin. Now it's facing a back-to-school supply strain
▼ + stars: | 2023-08-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +8 min

Ten milligram tablets of the hyperactivity drug, Adderall, made by Shire Plc. Adderall and alternative ADHD medications apart from other drugs are Schedule 2 controlled substances. Production limitationsEnding the shortages of Adderall and other ADHD medications is no easy task. That means increasing the production of one drug could potentially require reducing production — and potentially impacting supply — of another drug, according to Ergun. That includes Aytu BioPharma, which makes an ADHD drug that used to be in shortage.

Persons: Jb Reed, It's, Erin Fox, they've, David Margraf, Margraf, drugmakers, Ozlem Ergun, Ergun, Novartis's, Michael Ganio, ASHP's Ganio, RJ Sangosti, Josh Disbrow, Fox Organizations: Shire Plc, Jb, Bloomberg, Getty, and Drug Administration, CNBC, University of Utah, American Society of Health, System Pharmacists, Centers for Disease Control, University of Minnesota's, Infectious Disease, Northeastern University, Teva Pharmaceuticals, Amneal Pharmaceuticals, Sandoz, Purdue Pharma, Rhodes Pharmaceuticals, Drug, Fox, Pharmacists, Drug Enforcement Administration, MediaNews, Denver, FDA, DEA Locations: U.S, Commerce City , Colorado

☆ Redwire and Sierra team up to make drugs in space on inflatable habitat’s first mission
▼ + stars: | 2023-08-21 | by ( Michael Sheetz | In Michaeljsheetz | ) www.cnbc.com time to read: +1 min

An ADSEP with blue PIL-BOXs, hardware which will be delivered to Sierra Space for the LIFE habitat pathfinder mission. Space infrastructure company Redwire is putting a biotech technology test bed on Sierra Space's first mission with its inflatable space habitat, establishing a new partnership between the two companies to make drugs in orbit. "It's an incredible moment for Redwire, an incredible moment for Sierra," Mike Gold, Redwire's chief growth officer, told CNBC. Redwire is not alone in targeting that market, with startups like Varda and Space Forge also working on such test beds. The idea is to manufacture drugs in space, leveraging the environment to create unique materials, that would be returned for use on Earth.

Persons: Mike Gold, Varda Organizations: Space, LIFE, pathfinder, CNBC, Space Forge Locations: Space's, Space

☆ Barclays: Novo Nordisk and Eli Lilly have first-move advantage in the obesity drug race
▼ + stars: | 2023-08-10 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBarclays: Novo Nordisk and Eli Lilly have first-move advantage in the obesity drug raceEmily Field, Head of European Pharmaceutical Research at Barclays, discusses Novo Nordisk, Eli Lilly, and competition in the weight-loss/obesity drug space.

Persons: Eli Lilly, Emily Field Organizations: Barclays, Novo Nordisk, European Pharmaceutical Research

July 18 (Reuters) - Johnson & Johnson (JNJ.N) sued the U.S. government on Tuesday, becoming the latest drugmaker seeking to block a program that gives the Medicare government health insurance plan the power to negotiate lower drug prices. The pharmaceutical industry says the drug price negotiation program under President Joe Biden's signature Inflation Reduction Act law will curtail profits and compel drugmakers to curb development of groundbreaking new treatments. The U.S. Centers for Medicare and Medicaid Services (CMS) in September is expected to select the first 10 drugs to target for negotiations with settled prices set to take effect in 2026. The law is on our side," a spokesperson for the U.S. Department of Health and Human Services said in a statement. It broadly follows the other related lawsuits, arguing that the program is unconstitutional and amounts to "confiscation of constitutionally protected property."

Persons: Johnson, Joe Biden's, drugmakers, Biden, Janssen, Bhanvi, Michael Erman, Krishna Chandra Eluri, Susan Heavey Organizations: Johnson, U.S, drugmakers Bristol Myers Squibb, Merck & Co, U.S . Chamber of Commerce, Pharmaceutical Research, Manufacturers of America, Commerce, U.S . Centers, Medicare, Medicaid Services, U.S . Department of Health, Human Services, District of, Thomson Locations: U.S, District of New Jersey, Bengaluru, New Jersey

July 18 (Reuters) - Johnson & Johnson (JNJ.N) sued the U.S. government on Tuesday, becoming the latest drugmaker seeking to block enforcement of a program that gives Medicare the power to negotiate drug prices. The pharmaceutical industry says the drug price negotiation program that is part of President Joe Biden's signature Inflation Reduction Act (IRA) will curtail profits and compel them to pull back on developing groundbreaking new treatments. U.S. drugmakers Bristol Myers Squibb (BMY.N), Merck & Co (MRK.N) and the U.S. Chamber of Commerce as well as industry lobbies Pharmaceutical Research and Manufacturers of America have also sued the government over the plan. The Biden administration hopes to save $25 billion annually by 2031 by having Medicare, the government health plan for people 65 and over, negotiate prices for some of its costliest medicines. Reporting by Bhanvi Satija in Bengaluru; Editing by Krishna Chandra EluriOur Standards: The Thomson Reuters Trust Principles.

Persons: Johnson, Joe Biden's, Biden, Bhanvi, Krishna Chandra Organizations: Johnson, U.S, drugmakers Bristol Myers Squibb, Merck & Co, U.S . Chamber of Commerce, Pharmaceutical Research, Manufacturers of America, Thomson Locations: Bengaluru

☆ Chamber of Commerce asks judge to block Medicare drug price negotiations before October
▼ + stars: | 2023-07-12 | by ( Spencer Kimball | ) www.cnbc.com time to read: +3 min

The U.S. Chamber of Commerce on Wednesday asked a federal judge in Ohio to block Medicare's new powers to negotiate drug prices before Oct. 1. They argued that the drug negotiations violate the First and Fifth Amendments of the U.S. Constitution, as well as the separation of powers. The Chamber asked Judge Thomas Rose on Wednesday to block the negotiations before they get under way because they violate the due process clause. Drugmaker Abbvie , a member of the U.S. Chamber and the Dayton, Ohio area chamber, fears that its blood cancer drug Imbruvica will be selected for the negotiations this fall. The Medicare drug price negotiations do not provide these safeguards and impose price caps that are well below a drug's market value, the chamber's lawyers said.

Persons: Xavier Becerra, Drugmakers, Judge Thomas Rose, Drugmaker, Engler, Michael Staff Organizations: U.S . Chamber, Washington , D.C, Commerce, Wednesday, Medicare, Human Services, Constitution, HHS, Sixth Circuit, Appeals, Michigan Bell Telephone Co, Companies, Staff, Merck, Bristol Myers Squibb, Pharmaceutical Research, Manufacturers of America, U.S Locations: Washington ,, Ohio, Dayton , Ohio, Michigan, U.S

☆ Medicare will allow pharmaceutical companies to publicly discuss drug price negotiations
▼ + stars: | 2023-06-30 | by ( Spencer Kimball | ) www.cnbc.com time to read: +3 min

Medicare on Friday said it will allow pharmaceutical companies to publicly discuss the program's historic drug price negotiations, dropping a confidentiality requirement that the industry argued violated the First Amendment in lawsuits filed this month. It also required companies to destroy any information within 30 days if the drug is no longer selected for negotiations. The Inflation Reduction Act, passed last year, empowered Medicare to directly negotiate with pharmaceutical companies over prices for the first time. "Pharmaceutical companies have made record profits for decades," Becerra said in a statement. "Now they're lining up to block this Administration's work to negotiate for better drug prices for our families.

Persons: Kathy Hochuls, Biden, Bristol Myers Squibb, Xavier Becerra, Becerra Organizations: Medicare, U.S . Merck, U.S . Chamber of Commerce, Bristol Myers Squibb, Pharmaceutical Research, Manufacturers, America, Merck, Bristol, U.S . Constitution, Health, Human Services, Pharmaceutical Locations: U.S, U.S .

June 30 (Reuters) - The U.S. government on Friday revised its guidance for its Medicare drug price negotiation process, allowing drug companies to publicly discuss the talks, but did not make major changes likely to convince drugmakers to end their suits seeking to halt the program. In September, the U.S. Centers for Medicare and Medicaid Services (CMS) will select 10 of the Medicare program's costliest prescription medicines and negotiate price cuts to go into effect for 2026. That guidance precluded drug makers from talking about the negotiations and required them to eventually destroy data received from CMS. Industry group the Pharmaceutical Research and Manufacturers of America (PhRMA) made an additional claim that the price negotiation program violates the U.S. Constitution's Eight Amendment, which protects against excessive fines. The Biden administration's drug pricing reform aims to save $25 billion annually by 2031 through price negotiations for the drugs most costly to Medicare.

Persons: drugmakers, Joe Biden, Chiquita Brooks, LaSure, Bristol Myers, Merck, PhRMA, Tahir Amin, Amin, Michael Erman, Mark Potter, Nick Zieminski Organizations: U.S, U.S . Centers, Medicare, Medicaid Services, Merck & Co, Bristol Myers Squibb, U.S . Chamber of Commerce, CMS, Merck, Bristol, Industry, Pharmaceutical Research, Manufacturers of America, Reuters, Initiative for Medicines, Biden, Thomson Locations: U.S

☆ Pharmaceutical trade group sues Biden administration over Medicare drug price negotiations
▼ + stars: | 2023-06-21 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

The pharmaceutical industry's largest lobbying group and two other organizations Wednesday sued the Biden administration over Medicare's new powers to slash drug prices for seniors under the Inflation Reduction Act. Pharmaceutical Research and Manufacturers of America, along with the National Infusion Center Association and the Global Colon Cancer Association, argue that the Medicare negotiations with drugmakers violate the U.S. Constitution, in a complaint filed in federal district court in Texas. The groups asked the court to declare the program unconstitutional and prevent the Department of Health and Human Services from implementing Medicare negotiations without "adequate procedural protections" for drug manufacturers. It marks the fourth lawsuit challenging the controversial provision of the Inflation Reduction Act, which became law last summer in a major victory for President Joe Biden and Democratic lawmakers. The lawsuit also argues the policy violates due process by denying pharmaceutical companies and the public input on how Medicare negotiations will be implemented.

Persons: Eli Lilly, Johnson, Joe Biden, PhRMA —, drugmakers, Stephen Ubl, Ubl Organizations: New York Stock Exchange, Biden, Pharmaceutical Research, Manufacturers of America, National, Center Association, Global Colon Cancer Association, drugmakers, Constitution, Pfizer, Johnson, of Health, Human Services, HHS, Democratic, Merck, Bristol Myers Squibb —, U.S . Chamber of Commerce, PhRMA Locations: U.S, Texas

☆ Drugmakers aim to strike down Medicare drug-price negotiations at Supreme Court
▼ + stars: | 2023-06-20 | by ( Spencer Kimball | ) www.cnbc.com time to read: +10 min

And Bristol Myers Squibb is trying protect its blood thinner Eliquis, which brought in $11.8 billion in sales last year, or about 25% of the company's $46 billion total revenue for 2022. Long legal battle aheadMerck, the chamber and Bristol Myers Squibb filed their lawsuits ahead of two key deadlines. Bristol Myers Squibb did not either. If circuit court decisions on the matter contradict one another, the Supreme Court would step in to decide the issue, Bagby said. Bristol Myers Squibb made an identical argument in its complaint.

Persons: Richard A, Gonzalez, Pascal Soriot, Giovanni Caforio, Jennifer Taubert, Johnson, Kenneth C, Frazier, Albert Bourla, Olivier Brandicourt, Win Mcnamee, Drugmaker Merck, Drugmaker, Bristol Myers Squibb, PhRMA, Eli Lilly, Merck, Bristol Myers, Robin Feldman, Nicholas Bagley, Bagley, Gretchen Whitmer, Chris Meekins, Raymond James, Antonin Scalia, Brett Kavanaugh, Neil Gorsuch, Meekins, Long, Xavier Becerra, Randolph Daniel Moss, Barack Obama, Judge Thomas M, Rose, George W, Bush, Kelly Bagby, Bagby, Amgen, Donald Trump, Karine Jean, Pierre, Biden, Jean, we'll, Becerra, Feldman Organizations: Senate, AbbVie Inc, AstraZeneca, Myers Squibb Co, Janssen Pharmaceuticals, Johnson, Merck & Co, Inc, Pfizer, Sanofi, Getty, U.S . Chamber of Commerce, Bristol Myers Squibb, Washington , D.C, Southern, Southern District of, Democratic Party, U.S, Merck, Bristol, Pharmaceutical Research, Manufacturers of America, CNBC, Medicare, University of California College of, Justice Department, Michigan Gov, Bristol Myers, Human Services, Centers, Services, AARP Foundation, HHS, AARP, Specialty Pharmacy, Reuters, Supreme, Appeals, Democratic, U.S . Sixth, Republican, Third, White Locations: America, Washington , DC, Bristol, U.S, Washington ,, Southern District, Southern District of Ohio, New Jersey, Commerce's Dayton , Ohio, San Francisco

Search resuls for: "Pharmaceutical Research"

25 mentions found